Brokers Issue Forecasts for Bristol-Myers Squibb Company’s Q1 2018 Earnings (BMY)
Bristol-Myers Squibb Company (NYSE:BMY) – Analysts at William Blair issued their Q1 2018 earnings estimates for Bristol-Myers Squibb in a report released on Monday. William Blair analyst M. Phipps anticipates that the biopharmaceutical company will post earnings of $0.75 per share for the quarter. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Bristol-Myers Squibb’s Q2 2018 earnings at $0.75 EPS, Q3 2018 earnings at $0.78 EPS and Q4 2018 earnings at $0.76 EPS.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.01. The business had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.69 earnings per share. COPYRIGHT VIOLATION WARNING: This story was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/09/13/brokers-issue-forecasts-for-bristol-myers-squibb-companys-q1-2018-earnings-bmy.html.
A number of other equities analysts have also recently commented on BMY. BidaskClub raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Credit Suisse Group reaffirmed a “hold” rating on shares of Bristol-Myers Squibb in a research note on Friday, September 8th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. Vetr raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.08 price target for the company in a research note on Thursday, August 17th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $66.00 price target on shares of Bristol-Myers Squibb in a research note on Monday. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $62.54.
Shares of Bristol-Myers Squibb (NYSE:BMY) traded down 0.0882% during trading on Wednesday, hitting $62.9644. 325,646 shares of the stock traded hands. The stock has a market cap of $103.26 billion, a PE ratio of 22.9965 and a beta of 1.18. The firm’s 50-day moving average price is $57.73 and its 200-day moving average price is $55.76. Bristol-Myers Squibb has a 12 month low of $46.01 and a 12 month high of $63.47.
In related news, Director Theodore R. Samuels II bought 6,000 shares of the company’s stock in a transaction on Wednesday, August 2nd. The shares were bought at an average price of $55.94 per share, with a total value of $335,640.00. Following the transaction, the director now owns 18,000 shares in the company, valued at $1,006,920. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the sale, the senior vice president now directly owns 46,297 shares in the company, valued at approximately $2,777,820. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by insiders.
A number of large investors have recently added to or reduced their stakes in BMY. Vanguard Group Inc. boosted its holdings in shares of Bristol-Myers Squibb by 0.3% in the 2nd quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock valued at $6,611,829,000 after acquiring an additional 333,685 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Bristol-Myers Squibb by 2.4% in the 2nd quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock valued at $5,541,612,000 after acquiring an additional 2,367,864 shares during the last quarter. State Street Corp boosted its holdings in shares of Bristol-Myers Squibb by 1.8% in the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock valued at $3,746,446,000 after acquiring an additional 1,223,457 shares during the last quarter. Dodge & Cox boosted its holdings in shares of Bristol-Myers Squibb by 1.6% in the 2nd quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock valued at $1,648,168,000 after acquiring an additional 459,271 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Bristol-Myers Squibb by 3.9% in the 2nd quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock valued at $1,339,612,000 after acquiring an additional 910,496 shares during the last quarter. 68.80% of the stock is currently owned by institutional investors.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.